Neogen (NEOG) 2024 Wells Fargo Healthcare Conference summary

Operational performance and recent results

• First quarter results aligned with expectations set during Q4 earnings in July.

• Shipping and operational challenges from 2024 have been resolved and sustained improvements are seen in 2025.

• Some demand headwinds persist as a result of prior execution issues, but customer feedback and sales organization responses are encouraging.

• Customer trust is being rebuilt, with some returning and positive conversations underway.

• Integration of the 3M business is largely complete, with only Petrifilm manufacturing integration remaining.

Market conditions and growth outlook

• Animal Safety business is at the low end of its cycle, with expectations for eventual recovery.

• Food production volumes have been negative for over six quarters, impacting growth but not resulting in negative revenue.

• Food safety market is expected to recover gradually, dependent on macroeconomic factors.

• International markets, especially in Europe and Asia, present significant growth opportunities.

• Regulatory and awareness drivers support long-term growth, with the company now positioned as the largest food safety-specific business.

Margin expansion and financial strategy

• Margin expansion will be driven primarily by growth, with incremental margins from both legacy and acquired product lines.

• Post-integration cost structure and investments in procurement and manufacturing are expected to improve operating and gross margins.

• Targeting a 30% margin profile post-integration, with improvements expected as markets recover.

• Free cash flow is expected to turn positive in 2025 as integration spending declines.

• Capital allocation will shift from integration to deleveraging and eventually back to M&A as leverage approaches 2x.